** Shares of Divi's Laboratories DIVI.NS gain ~4% at 4,895
rupees
** DIVI top pct gainer on Nifty 50 .NSEI and Nifty pharma
index .NIPHARM
** U.S. appeals court puts stay order on US FDA's approval
for generic version of Novartis' NOVN.S top-selling heart
failure drug Entresto, for which DIVI makes the API Sacubitril,
Bloomberg Law reports
** Novartis did not immediately respond to Reuters' request
for comment
** "While litigation is still ongoing, the stay on approval
blocks the launch of generic version of Entresto for now, which
is a positive for DIVI," said Shrikant Akolkar of Nuvama
Institutional Equities
** DIVI fell the most in nearly 16 months on Aug. 14 when
Novartis lost initial bid to block generic versions of Entresto
** Stock up ~26% YTD vs ~34% gains in pharma index
(Reporting by Kashish Tandon in Bengaluru)
((kashish.tandon@thomsonreuters.com))